A subset of ocular adnexal marginal zone lymphomas may arise in association with IgG4-related disease by Kyotaro, Ohno et al.
1Scientific RepoRts | 5:13539 | DOi: 10.1038/srep13539
www.nature.com/scientificreports
A subset of ocular adnexal 
marginal zone lymphomas may 
arise in association with IgG4-
related disease
Kyotaro Ohno1,*, Yasuharu Sato1,2,*, Koh-ichi Ohshima3, Katsuyoshi Takata1, 
Tomoko Miyata-Takata1, Mai Takeuchi1, Yuka Gion1, Tomoyasu Tachibana4, Yorihisa Orita5, 
Toshihiro Ito6, Steven H. Swerdlow7 & Tadashi Yoshino1
We previously suggested a relationship between ocular immunoglobulin (Ig)G4-related disease 
(IgG4-RD) and marginal zone lymphomas (MZLs). However, the cytokine background associated with 
these disorders and whether it differs between ocular adnexal MZLs with (IgG4-associated MZL) and 
without (IgG4-negative MZL) numerous IgG4+ plasma cells are unknown. In this study, we identified 
the mRNA expression pattern of Th2 and regulatory T-cell (Treg) cytokines in IgG4-RD and in IgG4-
associated MZL and IgG4-negative MZL using real-time polymerase chain reaction analysis. Ocular 
IgG4-RD and IgG4-associated MZL exhibited significantly higher expression ratios of interleukin 
(IL)-4/β-actin, IL-10/β-actin, IL-13/β-actin, transforming growth factor (TGF) β1/β-actin, and FOXP3/β-
actin than did IgG4-negative MZL (p < 0.05). This finding further supports our prior observations that 
a significant subset of ocular MZLs arises in the setting of IgG4-RD. Furthermore, the presence of a 
different inflammatory background in IgG4-negative MZLs suggests that IgG4-associated MZLs may 
have a different pathogenesis.
Immunoglobulin (Ig)G4-related disease (IgG4-RD) is a systemic syndrome characterized by dense lym-
phoplasmacytic infiltrates that are rich in IgG4+ plasma cells, fibrosis in the involved organ, and elevated 
serum IgG4 levels. IgG4-RD can affect almost any organ, including the pancreas, hepatobiliary duct, 
lacrimal and salivary glands, lung, kidney, retroperitoneum, aorta, and lymph nodes1–11.
Recent reports have described upregulation of T-helper-2 cells (Th2) and regulatory T-cell (Treg) 
cytokines in tissues with IgG4-RD, suggesting that the immune reaction mediated by these cytokines is 
responsible for the lesions12,13. This is in contrast to most extranodal marginal zone lymphomas (MZLs) 
that have a Th1 type inflammatory background, but similar to the Th2 background seen in a large cuta-
neous MZL subset that is also often IgG4-positive14–16.
Previously, we reported cases of ocular adnexal MZLs with numerous IgG4+ plasma cells that ful-
filled the histological diagnostic criteria for IgG4-RD; therefore, we suggested that MZLs can arise in 
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a background of IgG4-RD1. However, the expression pattern of cytokines in MZL lesions with IgG4+ 
plasma cells has not been clarified.
In this study of ocular IgG4-RD and MZLs with (IgG4-associated MZL) and without (IgG4-negative 
MZL) numerous IgG4+ plasma cells, we aimed to identify the mRNA expression patterns of Th2 and 
Treg cytokines and to determine the inflammatory background associated with benign and neoplastic 
ocular lymphoplasmacytic proliferations with numerous IgG4+ plasma cells that is distinct from that 
associated with ocular IgG4-negative MZL.
Material and Methods
Samples and clinical review. Formalin-fixed excisional biopsies from the ocular adnexal region of 
patients were selected, including 11 patients with IgG4-RD, 11 with IgG4-negative MZL, and 6 with 
IgG4-associated MZL (Table  1). All MZL lesions were primary tumors, and there was no other organ 
involvement. None of the patients were treated prior to the biopsy. Clinical data including serum IgG4 
and IgG levels were obtained when available. The IgG4 and IgG levels were measured by routine labora-
tory blood tests. Informed consent for the use of their samples in research was obtained from all patients.
Case 























1 IgG4-RD 47 F lacrimal gland 113 135 0.837 n.e. n.e.
2 IgG4-RD 60 M orbit 178 309 0.575 n.e. n.e.
3 IgG4-RD 66 F lacrimal gland 260 365 0.713 106 1400 0.076
4 IgG4-RD 73 M lacrimal gland 137 198 0.690 136 1437 0.095
5 IgG4-RD 56 F lacrimal gland 177 275 0.642 n.e. n.e.
6 IgG4-RD 61 M orbit 298 440 0.678 3320 4168 0.797
7 IgG4-RD 66 M lacrimal gland 365 409 0.892 969 2454 0.395
8 IgG4-RD 60 F orbit 184 223 0.825 120 1499 0.080
9 IgG4-RD 58 F orbit 207 248 0.836 376 1351 0.278
10 IgG4-RD 36 F orbit 160 174 0.918 561 1958 0.287
11 IgG4-RD 72 M orbit 311 474 0.656 n.e. n.e.
12 IgG4− MZL 74 M conjunctiva 0 9 0.000 n.e. n.e.
13 IgG4− MZL 56 F conjunctiva 16 108 0.146 n.e. n.e.
14 IgG4− MZL 69 M lacrimal gland 44 259 0.171 n.e. n.e.
15 IgG4− MZL 72 M conjunctiva 49 164 0.297 n.e. n.e.
16 IgG4− MZL 69 M orbit 47 669 0.071 n.e. n.e.
17 IgG4− MZL 66 F lacrimal gland 0 15 0.000 19.3 962 0.020
18 IgG4− MZL 71 F lacrimal gland 25 605 0.041 n.e. n.e.
19 IgG4− MZL 61 M orbit 0 4 0.000 n.e. n.e.
20 IgG4− MZL 82 M orbit 0 26 0.000 166 1520 0.109
21 IgG4− MZL 39 M conjunctiva 2 17 0.100 n.e. n.e.
22 IgG4− MZL 74 F conjunctiva 1 12 0.111 n.e. n.e.
23 IgG4+ MZL 57 F lacrimal gland 128 183 0.699 n.e. n.e.
24 IgG4+ MZL 72 M orbit 128 152 0.838 760 2709 0.281
25 IgG4+ MZL 65 F lacrimal gland 143 300 0.475 116 1450 0.080
26 IgG4+ MZL 56 M orbit 189 219 0.863 475 1536 0.309
27 IgG4+ MZL 42 F lacrimal gland 123 152 0.807 n.e. n.e.
28 IgG4+ MZL 71 F lacrimal gland 147 450 1844 0.244
Table 1.  Histological and serological findings. IgG4-RD, IgG4-related disease; IgG4− MZL, IgG4-negative 
marginal zone lymphoma; IgG4+ MZL, IgG4-associated marginal zone lymphoma; n.e., not examined. 
Normal ranges of serum IgG and IgG4 are shown in square brackets. In case no. 28, number of IgG+ cells is 
not shown because tumor cells produce IgG.
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Real-time quantitative polymerase chain reaction (PCR). The following evaluations were car-
ried out in accordance with the approved guidelines. All experimental protocols were approved by the 
Institutional Review Board at Okayama University. Total RNA was extracted from the paraffin-embedded 
sections of all samples using an miRNeasy FFPE Kit (QIAGEN, Valencia, CA, USA). cDNA was prepared 
using a SuperScript VILO MasterMix kit (Invitrogen, Carlsbad, CA, USA). Multiplex real-time PCR was 
performed for quantitative analysis, according to a standard protocol, using TaqMan Gene Expression 
Assays (Applied Biosystems, Foster City, CA, USA), a Step One Plus Real-Time PCR System (Applied 
Biosystems), and specific primers and probes for FOXP3 (Hs01085834_m1), transforming growth fac-
tor (TGF)β 1 (Hs00998133_m1), interleukin (IL)-4 (Hs00174122_m1), IL-5 (Hs00174200_m1), IL-10 
(Hs00961622_m1), IL-13 (Hs00174379_m1), and β -actin (Hs99999903_m1) (Applied Biosystems). The 
PCR cycling conditions were as follows: 20 s at 95 °C, 50 cycles of 1 s at 95 °C, and 20 s at 60 °C. The 
expression of each target was normalized to that of β -actin, which was used as an endogenous control.
Histological examination, immunohistochemistry, and in situ hybridization. Serial sections 
(4 μ m) were cut from the block of paraffin-embedded tissue, stained with hematoxylin and eosin, and 
used for the following immunohistochemical stains: CD20 (L26 [1:400]; DAKO, Glostrup, Denmark), 
CD3 (LN10 [1:200]; Novocastra, Newcastle, UK), CD5 (4c7 [1:50]; Novocastra), CD10 (56C6 [100:1]; 
Novocastra), CyclinD1 (SP4 [1:50]; Nichirei, Tokyo, Japan), Ki-67 (MIB-1 [1:2500]; Novocastra), IgG 
(polyclonal [1:20,000]; DAKO), and IgG4 (HP6025 [1:10000]; The Binding Site, Birmingham, UK). 
Following immunostaining using an automated Bond Max stainer (Leica Biosystems, Melbourne, 
Germany), the numbers of IgG4+ and IgG+ cells were estimated in areas with the highest density of 
IgG4+ cells. In accordance with the consensus statement on the pathological features of IgG4-RD17, three 
different high-power fields (HPFs) (total magnification, × 400) were examined to calculate the average 
number of IgG4+ cells per HPF and the IgG4+/IgG+ cell ratio. In situ hybridization was also performed 
for κ and λ -light chains (Leica Biosystems) using a Bond Max stainer.
Molecular genetic analysis. PCR molecular genetic analysis for immunoglobulin heavy chain 
gene rearrangements was performed as previously described18–20. The primers used in this study were: 
5′ -TGG[A/G]TCCG[C/A]CAG[G/C]C[T/C][T/C]C[A/C/G/T]GG-3′ as an upstream consensus V-region 
primer; 5′ -TGAGGAGACGGTGACC-3′ as a consensus J-region primer, and 5′ -GTGACCAGGGT[A/C/
G/T]CCTTGGCCCCAG-3′ as a consensus J-region primer18–20.
Statistical analysis. All statistical analyses were performed using the Mann–Whitney U-test with 
SPSS software (version 14.0; SPSS, Chicago, IL, USA).
Results
Histological/phenotypic examinations. IgG4-related disease. Biopsies from the 11 patients with 
IgG4-RD showed marked lymphoplasmacytic infiltration with or without dense fibrosis, scattered eosin-
ophils, and interspersed reactive lymphoid follicles. No light-chain restrictions were noted. All cases 
demonstrated >100 IgG4+ cells/HPF, and the IgG4+/IgG+ cell ratio was > 40% (Fig. 1).
IgG4-negative marginal zone lymphoma. The 11 IgG4-negative MZLs showed dense infiltration by 
small- to medium-sized CD20+, CD3−, CD5−, and CD10− lymphoid cells with a Ki-67 labeling index 
< 10% (Fig. 2). Fibrosis and eosinophil infiltration were rarely present. In 3 specimens (cases 15, 16, and 
18), in situ hybridization was performed, and polytypic plasma cells were detected. PCR revealed clonal 
immunoglobulin heavy chain rearrangement in 1 of 2 cases tested (case 22 but not case 15). All cases 
revealed few, if any, IgG4+ cells, and the IgG4+/IgG+ cell ratio was < 40%.
IgG4-associated marginal zone lymphoma. The 6 IgG4-associated MZLs were histologically and pheno-
typically similar to the IgG4-negative MZLs except that there were numerous IgG4+ cells, and fibrosis 
was present in 3 cases (cases 26, 27, and 28) (Table 1, Fig. 3). All cases had either clonal immunoglobulin 
heavy chain rearrangement (cases 23, 25, and 26) and/or were monotypic based on in situ hybridization 
for κ and λ (cases 24, 25, 27, and 28). Based on the distribution of the IgG4+ cells and non-dominant 
light chain staining, the IgG4+ cells appeared to be polytypic. In all 6 cases, >100 IgG4+ cells/HPF were 
detected; therefore, these cases fulfilled the histological diagnostic criteria for IgG4-RD. Furthermore, in 
5 cases, the IgG4+/IgG+ cell ratio was > 40%. In case 28, the IgG4+/IgG+ cell ratio was not estimated 
because the lymphoma cells present were IgG positive, and the much fewer IgG4+ cells appeared to 
reflect a polytypic IgG+ population that could not be quantitated (Fig. 4).
Serological analysis. Serum IgG4 and IgG levels were determined in 7 patients with ocular IgG4-RD, 
in 2 patients with IgG4-negative MZL, and in 4 patients with IgG4-associated MZL (Table  1). Serum 
IgG4 levels were > 135 mg/dL (reference range, 4.8–105) in 5 of 7 tested patients with IgG4-RD, 1 of 2 
patients with IgG4-negative MZL, and 3 of 4 patients with IgG4-associated MZL.
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Expression pattern of Th2 and Treg cytokines. The expressions of IL-4, IL-5, IL-10, IL-13, 
TGFβ 1, and β -actin in the samples were quantitatively analyzed using real-time PCR. Ocular IgG4-RD 
and the IgG4-associated MZL samples exhibited significantly higher expression ratios of IL-4/β -actin, 
IL-10/β -actin, IL-13/β -actin, and TGFβ 1/β -actin than did the IgG4-negative MZL samples (p < 0.05) 
(Fig. 5). No significant differences were found for IL-5/β -actin expression.
Expression of FOXP3. The ocular IgG4-RD and IgG4-associated MZL biopsies exhibited signifi-
cantly higher expression ratios of FOXP3/β -actin than did the IgG4-negative MZL specimens (p < 0.05) 
(Fig. 6).
Discussion
The Th1/Th2 balance is considered important for healthy immune responses, and a Th1/Th2 imbalance 
can cause immune-mediated disease. Th1-dominant immune responses are noted in patients with rheu-
matoid arthritis, type 1 diabetes, and multiple sclerosis, whereas Th2-dominant immune responses are 
observed in patients with type 1 hypersensitivity disorders, such as allergies or asthma21. Extranodal 
MZLs are considered to arise in a background of chronic inflammation. High levels of Th1-type 
cytokines (interferon [IFN]-γ and IL-2) are typically found in the tumor environment of many mucosa 
associated lymphoid tissue (MALT) lymphomas22,23. Moreover, most extranodal MZLs express high lev-
els of CXCR3, which is the receptor for IFN-γ -induced chemokines24–26. In contrast, a major subset of 
cutaneous MZLs typically shows heavy chain class switching and has a Th2 background14,15. In addition, 
39% of cutaneous MZLs with plasmacytic differentiation are reported to be IgG4+, whereas an ocular 
MZL was the only non-cutaneous IgG4+ MZL found in the same study16.
Recently, high levels of Th2 cytokines (IL-4 and IL-13) and Treg cytokines (TGFβ 1 and IL-10) have 
been detected in tissues with IgG4-RD12. Costimulation with IL-4 and IL-10 is suggested to cause class 
switching to IgG427. Furthermore, upregulation of IL-13 induces eosinophil infiltration, and TGFβ 1 is 
considered to cause fibrosis in IgG4-RD lesions. In this study, we found higher levels of Th2 and Treg 
cytokines (including FOXP3) in lesions from patients with either IgG4-RD or ocular IgG4-associated 
MZL than in samples from patients with ocular adnexal IgG4-negative MZL. However, the expression 
levels of IL-5, which is a Th2 cytokine that promotes eosinophil infiltration, were not significantly dif-
ferent between sample types. These results indicate that IgG4-associated MZL is characterized by the 
Figure 1. IgG4-related disease (case 6). Marked lymphoplasmacytic infiltration with dense fibrosis, 
scattered eosinophils, and interspersed reactive lymphoid follicles are shown (A,B) (hematoxylin & eosin). 
Numerous IgG+ (C) and IgG4+ (D) cells are present with an IgG4+/IgG+ cell ratio > 40%.
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Figure 2. IgG4-negative marginal zone lymphoma (case 16). There is a diffuse proliferation of small- to 
medium-sized lymphoid cells (A,B) that are CD20+ (C) and CD3− (D). Numerous Igκ + plasma cells are 
present (E), but only very few Igλ + plasma cells (F). Some IgG+ (G) and IgG4+ (H) cells are present but the 
IgG4+/IgG+ cell ratio is < 40%.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:13539 | DOi: 10.1038/srep13539
Figure 3. IgG4-associated marginal zone lymphoma. The diffusely proliferating small- to medium-sized 
lymphoid cells [(A,B) case 26] are CD20+ (C) and CD3− (D). Infiltration of many IgG+ (E) and IgG4+ (F) 
cells are observed, but these cells are polytypic (G) (Igκ ) and (H) (Igλ ). The IgG4+/IgG+ cell ratio is > 40%.
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upregulation of Th2 and Treg cytokines, similar to IgG4-RD. Despite sharing a similar inflammatory 
background with class-switched cutaneous MZLs, and very much unlike most other MALT lymphomas, 
the ocular cases, with one exception, had IgG4+ plasma cells that were polytypic and not part of the 
neoplasm. An explanation for this difference remains to be established, and the heavy chain expressed 
by the ocular lymphomas is uncertain.
The mechanism for the development of ocular adnexal MZL is not clear. However, recent reports indi-
cated that Chlamydia psittaci infection is associated with the development of ocular adnexal MZL28–30. 
We previously suggested that ocular adnexal MZLs may arise in the setting of ocular IgG4-RD1, and 
others have reported cases of ocular adnexal lymphoma with IgG4+ cells, suggesting that they arose from 
IgG4-RD31. Moreover, a case involving two types of mass lesions in the same ophthalmic region has also 
been reported32. One of the lesions was typical of IgG4-RD, and the other was an MZL admixed with 
IgG4+ plasma cells. Because the two lesions were adjacent to each other, the MZL may have arisen in the 
setting of the IgG4-RD lesion. These reports and the results of the present study suggest that a subset of 
ocular MZLs may arise in the setting of IgG4-RD.
Patients with IgG4-RD are considered to be at high risk of MZLs as well as other malignancies, 
with malignancy considered a possible complication of IgG4-RD. Lung and colon cancers, as well as 
malignant lymphomas, are reported to occur in 10.4% of patients with IgG4-RD, an incidence that is 
approximately 3.5 times higher than that in the general population33. Although the mechanism through 
which neoplasms arise in a background of IgG4-RD remains unknown, a recent report suggests that 
Figure 4. IgG4-associated marginal zone lymphoma (case 28). Numerous plasmacytic cells are present 
(A,B) that are IgG+ (C). The lymphoma cells are κ light chain-restricted. (D) Igκ -in situ hybridization and 
(E) Igλ -in situ hybridization. Admixed IgG4+ plasma cells that appear to be polytypic are present (F).
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IgG4 subclass antibodies impair antitumor immunity against melanomas34. The authors reported that 
IgG4 antibodies did not induce antitumor immunity, unlike IgG1 antibodies; rather, they inhibited the 
antitumor activity of the IgG1 antibodies. Therefore, although IgG4 subclass antibodies do not specifi-
cally induce neoplasms, they may create an environment where induced malignant neoplasms are more 
likely to grow.
In the current study, upregulation of FOXP3 was detected in cases of IgG4-RD and IgG4-associated 
MZL lesions. This is consistent with an earlier report describing the presence of numerous FOXP3+ 
cells in IgG4-RD12. FOXP3 is a marker of Tregs and is a central control element in their development 
and function. Because Tregs have been reported to suppress inflammation, including tumor immunity35, 
FOXP3+ Tregs may infiltrate lesions associated with IgG4-RD and further suppress tumor immunity, also 
promoting the growth of neoplasms.
Although steroid therapy is effective in IgG4-RD, the most effective treatment for MZLs arising in 
the setting of IgG4-RD is uncertain. Although evaluation of additional cases of IgG4-associated MZLs 
is needed to determine the treatment and prognosis, radiation or chemotherapy may be necessary. 
Therefore, when IgG4-RD is diagnosed, the lesion should be assessed to determine if it includes an 
MZL component. The possible tumor-promoting environment of IgG4-RD supports treatment for these 
patients before an MZL arises, in addition to ongoing follow-up.
Conclusion
IgG4-associated MZL is characterized by the upregulation of Th2 and regulatory cytokines, as is the case 
in IgG4-RD, but unlike the cytokine background of IgG4-negative MZLs. The current results further 
Figure 5. Cytokine levels were measured by relative quantification of mRNA. mRNA expression of 
Th2 cytokines (IL-4, IL-13) and regulatory cytokines (TGFβ 1, IL-10) are significantly higher in the ocular 
adnexal regions from biopsies with IgG4-related disease and IgG4-associated marginal zone lymphoma than 
in the ocular adnexal regions from IgG4-negative marginal zone lymphomas. The expression levels of IL-5 
are not significantly different. Data represent mean ± standard deviation (SD) values. Significant differences 
between groups were determined using the Mann-Whitney U test. (*p < 0.05). IgG4− MZL, IgG4-negative 
marginal zone lymphoma; IgG4-RD, IgG4-related disease; IgG4+ MZL, IgG4-associated marginal zone 
lymphoma.
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suggest that a subset of MZLs may arise in an IgG4-RD setting and that this subset of MZLs may have 
a different pathogenesis than IgG4-negative MZLs.
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